GlassScriptPhysician profile
Wendy D Davis
NPI 1225896608
$1,536.48
in general payments reported to CMS, 2019-2025
21 companies · $998 in 2025
The $998 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $539 · 2025: $998.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,536.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,536.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $271.54 | 2024-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $182.59 | 2024-2025 | Caplyta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $168.64 | 2024-2025 | Relistor, Trulance, Xifaxan |
| Exact Sciences Corporation | $103.24 | 2024-2025 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $94.72 | 2024-2025 | Airsupra, Breztri |
| Novo Nordisk INC | $92.68 | 2024-2025 | Ozempic, Wegovy, Rybelsus |
| Axsome Therapeutics, INC. | $92.33 | 2024-2025 | Auvelity |
| Lilly USA, LLC | $75.88 | 2024-2025 | Mounjaro |
| Braeburn INC. | $68.22 | 2024-2025 | Brixadi |
| Amgen INC. | $60.20 | 2024-2025 | Repatha, Otezla, Repatha |
| Pfizer INC. | $43.23 | 2025 | |
| Almatica Pharma LLC | $39.68 | 2024 | Loreev Xr |
| Otsuka America Pharmaceutical, INC. | $35.77 | 2024-2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $34.94 | 2024-2025 | |
| Phathom Pharmaceuticals, INC. | $34.37 | 2025 | Voquezna |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.56 | 2025 | |
| Lundbeck LLC | $28.37 | 2025 | Rexulti |
| Indivior INC. | $26.51 | 2024 | Sublocade |
| Corcept Therapeutics | $25.26 | 2025 | Korlym |
| Tolmar, INC. | $15.18 | 2024 | |
| Vertex Pharmaceuticals Incorporated | $14.57 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wendy Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.